{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T18:00:17Z","timestamp":1787853617138,"version":"build-2784847793"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22277131"],"award-info":[{"award-number":["22277131"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["8217155 8"],"award-info":[{"award-number":["8217155 8"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002367","name":"Chinese Academy of Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002367","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFC3603300"],"award-info":[{"award-number":["2023YFC3603300"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.jconrel.2024.08.044","type":"journal-article","created":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T18:12:41Z","timestamp":1725300761000},"page":"627-638","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["Liver-targeting chimeras as a potential modality for the treatment of liver diseases"],"prefix":"10.1016","volume":"374","author":[{"given":"Chuanjie","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongzhang","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiqin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinhui","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengyuan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiwen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runzi","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiwen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengjie","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyadarshani Nadeeshika","family":"Samarawickrama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiting","family":"Zi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonghan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2024.08.044_bb0005","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jhep.2018.09.014","article-title":"Burden of liver diseases in the world","volume":"70","author":"Asrani","year":"2019","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jconrel.2024.08.044_bb0010","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/hep.21347","article-title":"Global challenges in liver disease","volume":"44","author":"Williams","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.jconrel.2024.08.044_bb0015","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/s41575-023-00754-7","article-title":"Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment","volume":"20","author":"Llovet","year":"2023","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.jconrel.2024.08.044_bb0020","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","article-title":"Hepatocellular carcinoma","volume":"7","author":"Llovet","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.jconrel.2024.08.044_bb0025","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001624","article-title":"Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis","volume":"11","author":"Singal","year":"2014","journal-title":"PLoS Med."},{"key":"10.1016\/j.jconrel.2024.08.044_bb0030","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear-cell renal-cell carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2024.08.044_bb0035","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2024.08.044_bb0040","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41575-022-00704-9","article-title":"Evolving therapeutic landscape of advanced hepatocellular carcinoma","volume":"20","author":"Yang","year":"2023","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.jconrel.2024.08.044_bb0045","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.cell.2011.08.017","article-title":"BET Bromodomain inhibition as a therapeutic strategy to target c-Myc","volume":"146","author":"Delmore","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.jconrel.2024.08.044_bb0050","doi-asserted-by":"crossref","first-page":"16669","DOI":"10.1073\/pnas.1108190108","article-title":"Targeting MYC dependence in cancer by inhibiting BET bromodomains","volume":"108","author":"Mertz","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.jconrel.2024.08.044_bb0055","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.3389\/fonc.2019.01471","article-title":"Targeting BET proteins with a PROTAC molecule elicits potent anticancer activity in HCC cells","volume":"9","author":"Zhang","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.jconrel.2024.08.044_bb0060","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1158\/0008-5472.CAN-19-3674","article-title":"BRD4 levels determine the response of human lung Cancer cells to BET degraders that potently induce apoptosis through suppression of Mcl-1","volume":"80","author":"Zong","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2024.08.044_bb0065","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.molcel.2020.05.033","article-title":"The Long and the short of BRD4: two Tales in breast Cancer","volume":"78","author":"Zhang","year":"2020","journal-title":"Mol. Cell"},{"key":"10.1016\/j.jconrel.2024.08.044_bb0070","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/nature10509","article-title":"Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia","volume":"478","author":"Dawson","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2024.08.044_bb0075","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nature14898","article-title":"Transcriptional plasticity promotes primary and acquired resistance to BET inhibition","volume":"525","author":"Rathert","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2024.08.044_bb0080","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nature16508","article-title":"Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer","volume":"529","author":"Shu","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2024.08.044_bb0085","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1093\/annonc\/mdx157","article-title":"BET inhibitors: a novel epigenetic approach","volume":"28","author":"Doroshow","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jconrel.2024.08.044_bb0090","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41571-023-00736-3","article-title":"Protein degraders enter the clinic \u2014 a new approach to cancer therapy","volume":"20","author":"Chirnomas","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2024.08.044_bb0095","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/nchembio.2329","article-title":"Structural basis of PROTAC cooperative recognition for selective protein degradation","volume":"13","author":"Gadd","year":"2017","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.jconrel.2024.08.044_bb0100","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.chembiol.2017.09.010","article-title":"Lessons in PROTAC design from selective degradation with a promiscuous warhead","volume":"25","author":"Bondeson","year":"2018","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.jconrel.2024.08.044_bb0105","doi-asserted-by":"crossref","first-page":"5214","DOI":"10.1039\/D2CS00193D","article-title":"PROTACs: past, present and future","volume":"51","author":"Li","year":"2022","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.jconrel.2024.08.044_bb0110","doi-asserted-by":"crossref","first-page":"4313","DOI":"10.1039\/D3CS00100H","article-title":"Chemically induced degradation of epigenetic targets","volume":"52","author":"Kabir","year":"2023","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.jconrel.2024.08.044_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2022.103395","article-title":"PROTAC technology: a new drug design for chemical biology with many challenges in drug discovery","volume":"28","author":"Guedeney","year":"2023","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jconrel.2024.08.044_bb0120","doi-asserted-by":"crossref","first-page":"10009","DOI":"10.1021\/bi00495a001","article-title":"The asialoglycoprotein receptor: a model for endocytic transport receptors","volume":"29","author":"Spiess","year":"1990","journal-title":"Biochemistry"},{"key":"10.1016\/j.jconrel.2024.08.044_bb0125","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1096\/fj.99-0887com","article-title":"Novel hepatotrophic prodrugs of the antiviral nucleoside 9-(2-phosphonylmethoxyethyl)adenine with improved pharmacokinetics and antiviral activity","volume":"14","author":"Biessen","year":"2000","journal-title":"FASEB J."},{"key":"10.1016\/j.jconrel.2024.08.044_bb0130","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1089\/nat.2018.0736","article-title":"GalNAc-siRNA conjugates: leading the way for delivery of RNAi therapeutics","volume":"28","author":"Springer","year":"2018","journal-title":"Nucle. Acid Ther."},{"key":"10.1016\/j.jconrel.2024.08.044_bb0135","doi-asserted-by":"crossref","first-page":"8796","DOI":"10.1093\/nar\/gku531","article-title":"Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice","volume":"42","author":"Prakash","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jconrel.2024.08.044_bb0140","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/s41589-021-00770-1","article-title":"LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation","volume":"17","author":"Ahn","year":"2021","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.jconrel.2024.08.044_bb0145","doi-asserted-by":"crossref","first-page":"eadf6249","DOI":"10.1126\/science.adf6249","article-title":"Elucidating the cellular determinants of targeted membrane protein degradation by lysosome-targeting chimeras","volume":"382","author":"Ahn","year":"2023","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2024.08.044_bb0150","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1177\/0394632015572070","article-title":"BRD4 promotes tumor growth and epithelial-mesenchymal transition in hepatocellular carcinoma","volume":"28","author":"Zhang","year":"2015","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"10.1016\/j.jconrel.2024.08.044_bb0155","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1021\/acschembio.5b00216","article-title":"Selective small molecule induced degradation of the BET bromodomain protein BRD4","volume":"10","author":"Zengerle","year":"2015","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.jconrel.2024.08.044_bb0160","doi-asserted-by":"crossref","first-page":"8428","DOI":"10.1021\/acs.jmedchem.3c00302","article-title":"Recent advances in pro-PROTAC development to address on-target off-tumor toxicity","volume":"66","author":"Chen","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jconrel.2024.08.044_bb0165","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.jconrel.2024.08.044_bb0170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-020-00885-3","article-title":"Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy","volume":"13","author":"Li","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.jconrel.2024.08.044_bb0175","doi-asserted-by":"crossref","first-page":"16958","DOI":"10.1021\/ja505986a","article-title":"Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing","volume":"136","author":"Nair","year":"2014","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.jconrel.2024.08.044_bb0180","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1021\/acs.jmedchem.0c01846","article-title":"Antibody-mediated Delivery of Chimeric BRD4 Degraders. Part 2: improvement of in vitro antiproliferation activity and in vivo antitumor efficacy","volume":"64","author":"Dragovich","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jconrel.2024.08.044_bb0185","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/s41586-020-1930-8","article-title":"Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer","volume":"578","author":"Faivre","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2024.08.044_bb0190","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/psp4.12194","article-title":"Translational modeling of drug-induced myelosuppression and effect of pretreatment myelosuppression for AZD5153, a selective BRD4 inhibitor","volume":"6","author":"Collins","year":"2017","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"10.1016\/j.jconrel.2024.08.044_bb0195","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/s41575-019-0179-x","article-title":"Insights into the success and failure of systemic therapy for hepatocellular carcinoma","volume":"16","author":"Bruix","year":"2019","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.jconrel.2024.08.044_bb0200","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1038\/s41591-019-0668-z","article-title":"A selective BCL-X L PROTAC degrader achieves safe and potent antitumor activity","volume":"25","author":"Khan","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2024.08.044_bb0205","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nbt.3802","article-title":"Overcoming cellular barriers for RNA therapeutics","volume":"35","author":"Dowdy","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2024.08.044_bb0210","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/s41573-021-00219-z","article-title":"Noncoding RNA therapeutics\u2014challenges and potential solutions","volume":"20","author":"Winkle","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2024.08.044_bb0215","doi-asserted-by":"crossref","first-page":"3886","DOI":"10.1039\/D2CS00141A","article-title":"Degrader-antibody conjugates","volume":"51","author":"Dragovich","year":"2022","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.jconrel.2024.08.044_bb0220","doi-asserted-by":"crossref","first-page":"4361","DOI":"10.1039\/C8CS00676H","article-title":"Cleavable linkers in antibody\u2013drug conjugates","volume":"48","author":"Bargh","year":"2019","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.jconrel.2024.08.044_bb0225","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1021\/acs.jmedchem.0c01845","article-title":"Antibody-Mediated Delivery of Chimeric BRD4 Degraders. Part 1: Exploration of Antibody Linker, Payload Loading, and Payload Molecular Properties","volume":"64","author":"Dragovich","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jconrel.2024.08.044_bb0230","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/nbt.3212","article-title":"Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index","volume":"33","author":"Lyon","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2024.08.044_bb0235","doi-asserted-by":"crossref","first-page":"9161","DOI":"10.1021\/acs.jmedchem.3c00794","article-title":"Optimization of Drug-Linker to Enable Long-term Storage of Antibody\u2013Drug Conjugate for Subcutaneous Dosing","volume":"66","author":"Hobson","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jconrel.2024.08.044_bb0240","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio Cancer genomics portal: an open platform for exploring multidimensional Cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov."},{"key":"10.1016\/j.jconrel.2024.08.044_bb0245","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1038\/s41467-020-15838-0","article-title":"Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity","volume":"11","author":"He","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2024.08.044_bb0250","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/nrc1529","article-title":"Timeline: chemotherapy and the war on cancer","volume":"5","author":"Chabner","year":"2005","journal-title":"Nat. Rev. Cancer"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365924005947?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365924005947?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:45:05Z","timestamp":1777509905000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365924005947"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":50,"alternative-id":["S0168365924005947"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2024.08.044","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Liver-targeting chimeras as a potential modality for the treatment of liver diseases","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2024.08.044","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}